A consortium aiming to make New York a global leader in artificial intelligence would help Cornell play a role in shaping the future of AI, promote responsible research and development, create jobs and unlock opportunities focused on public good.
Researchers at Weill Cornell Medicine have catalogued the cellular response to stroke in a preclinical model, identifying the immune cells involved and the roles they may play in the days and weeks following a stroke.
Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis drug development.
A new study reveals that beyond providing a convenient way to store DNA in a tight space, the 3D organization of noncoding gene regulators in chromatin contributes to the control of key cell identity programs in early embryonic development.
A preclinical study has shown that colorectal pre-cancerous lesions known as serrated polyps, and the aggressive tumors that develop from them, depend on the ramped-up production of cholesterol, which points to the possibility of using cholesterol-lowering drugs to prevent or treat such tumors.
A clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found remaining on the anti-obesity drug tirzepatide promoted additional weight loss and preserved improvements in metabolic and cardiovascular health.
An intercampus collaboration that aims to provide digital health care tools to pregnant refugee women, who are at elevated risk for pregnancy complications but often afraid to seek medical care, has been awarded a National Academy of Medicine Catalyst Prize.
Removing race information from cardiovascular risk calculators – which predict the probability of developing heart disease – doesn’t affect patients’ risk scores, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Five people who had life-altering, seemingly irreversible cognitive deficits following moderate to severe traumatic brain injuries showed substantial improvements in their cognition and quality of life after receiving an experimental form of deep brain stimulation in a phase 1 clinical trial.
